incretins

News

Head to head figurine fights, red and blue

Lilly says orforglipron tops Novo pill in diabetes trial

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.

News

Black background scattered with red 'SALE' tickets

Novo Nordisk to cut GLP-1 prices in tough US market

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

After CagriSema blow, Novo reveals data for obesity 'triple'

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

The word Diabetes surrounded by tablets and syringes

NICE backs changes to NHS' diabetes care pathway

New guidance from NICE on type 2 diabetes management will shake up NHS treatment, with wider use of both SGLT2 inhibitors and GLP-1 agonists.

News

Novo Nordisk's Wegovy pill ad 'misleading', says FDA

Novo Nordisk has been criticised by the FDA for a TV ad for the Wegovy pill, which the agency claims makes "false and misleading" claims.

Lilly says orforglipron tops Novo pill in diabetes trial

Novo Nordisk to cut GLP-1 prices in tough US market

After CagriSema blow, Novo reveals data for obesity 'triple'

Head-to-head trial dents Novo Nordisk's obesity hopes

NICE backs changes to NHS' diabetes care pathway

Novo Nordisk's Wegovy pill ad 'misleading', says FDA

uniQure falls on long-term Huntington's gene therapy data

Discover a new era of healthcare panel engagement: Grounded ...

incretins

Editor's Picks